Alpha Fusion Inc. is a clinical-stage startup committed to transforming cancer treatment through the design and development of powerful and precise radiopharmaceuticals. Our radiopharmaceuticals utilize Astatine-211 (211At), alpha-emitting particles that are both effective against cancer and safe for patients. This innovation will significantly impact cancer patients who currently have limited treatment options.

“Astatine is a unique alpha-emitting isotope with a half-life of 7 hours, which does not undergo continuous decay. It is anticipated to be used in a wide range of cancer treatments. I have high expectations for Alpha Fusion Inc., the frontrunner in the development of astatine-based therapeutics.”
―Dr. Frederik Giesel , Chairman and Director of Nuclear Medicine at the University Hospital Düsseldorf